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Abstract 42 
Productive infections by human papillomaviruses (HPVs) are restricted to non-dividing, 
differentiated keratinocytes.  HPV early proteins E6 and E7 deregulate cell cycle 44 
progression and activate the host cell DNA replication machinery in these cells, changes 
essential for virus synthesis.  Productive virus replication is accompanied by abundant 46 
expression of the HPV E4 protein.  Expression of HPV1 E4 in cells is known to activate 
cell cycle checkpoints, inhibiting G2-to-M transition of the cell cycle and also suppressing 48 
entry of cells into S phase.  We report here that the HPV1 E4 protein, in the presence of a 
soluble form of the replication-licensing factor (RLF) Cdc6, inhibits initiation of cellular 50 
DNA replication in a mammalian cell-free DNA replication system.  Chromatin-binding 
studies show that E4 blocks replication initiation in vitro by preventing loading of RLFs 52 
Mcm2 and Mcm7 onto chromatin.  HPV1 E4 mediated replication inhibition in vitro and 
suppression of entry of HPV1 E4 expressing cells into S phase are both abrogated upon 54 
alanine replacement of arginine 45 in the full-length E4 protein (E1^E4), implying that 
these two HPV1 E4 functions are linked.  We hypothesize that HPV1 E4 inhibits 56 
competing host cell DNA synthesis in replication-activated suprabasal keratinocytes by 
suppressing licensing of cellular replication origins, thus modifying the phenotype of the 58 
infected cell in favour of viral genome amplification. 
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Introduction 60 
Human papillomaviruses (HPVs) are a large group (> 100 types) of small DNA viruses 
that replicate in keratinocytes of squamous epithelia.  HPV infections produce 62 
hyperproliferative warts that are in most instances benign.  A small subset of HPV types 
however form lesions on the skin, and on the oropharyngeal and anogenital tract mucosa, 64 
that have a significant risk of malignant transformation.  The most common cancer 
attributable to infection with the high-risk HPV types is cancer of the uterine cervix (35).  66 
Despite the differences in pathogenesis between virus types, their life cycles are similar 
(10), beginning with infection of keratinocytes within the basal cell compartment of 68 
squamous epithelia.  Here the HPV genome is replicated as a low copy (between 50-100 
copies per cell) episome in synchrony with the replication of the host cell genome, a 70 
process that requires HPV E1 and E2 functions.  HPV early proteins E6 and E7 act to 
expand the population of HPV infected keratinocytes once they migrate up from the basal 72 
layer, by stimulating cell cycle entry and cell survival.  The virus then utilizes the host 
cell’s replication machinery that has been activated in these cells to amplify the HPV DNA 74 
to many thousands of copies per cell during the vegetative stage of the life cycle.  Finally, 
the capsid proteins L1 and L2 are produced and new progeny are assembled in the most 76 
superficial cells prior to their release from the highly differentiated squames. 
A major protein produced during the HPV life cycle is the E4 protein.  It is expressed as an 78 
E1^E4 fusion protein from spliced transcripts formed between the N-terminus of the E1 
open-reading frame (ORF) and almost the complete ORF of E4 (21).  The precise function 80 
of E4 has not been defined, but loss of expression of the full-length E1^E4 polypeptide has 
a severe adverse effect on viral genome amplification of HPV types 16, 18 and 31 82 
genomes following introduction of mutant genomes unable to support E1^E4 expression 
into keratinocytes and subsequent induction of cellular differentiation (20, 38, 39).  Failure 84 
to complete the vegetative stage of the virus life cycle is also the outcome of loss of E1^E4 
expression in rabbit papillomas induced by a mutant cottontail rabbit papillomavirus 86 
genome (22).  These studies suggest that E4 function is necessary for efficient vegetative 
replication of the virus, a hypothesis supported by coincidence between onset of viral 88 
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genome amplification and induction of high-level E4 production in natural papillomavirus 
infections (23).  90 
Examination of E4 activity in epithelial cell cultures has revealed diverse biological 
actions that perhaps imply a multifunctional role for this viral protein in the virus life 92 
cycle.  These include disruption of ND10 body organization that might be required for 
viral DNA replication, either by organization of viral replication centres or by inactivation 94 
of an host anti-viral response mediated through the nuclear ND10 body (8, 29).  A potent 
G2 arrest function is a conserved function of E4 proteins between HPV types with 96 
dissimilar tropism and it is thought that division-arrest of infected cells might be necessary 
to support efficient viral DNA amplification (5, 13, 19).  E4 inclusion bodies found in the 98 
cytoplasm of cells of HPV1 skin warts contain a kinase SRPK1, a binding partner of 
E1^E4 proteins, that is associated with regulating the function of splicing factors (1).  100 
Sequestration of SRPK1 by E4 could be an HPV mechanism to regulate expression of viral 
late transcripts at the late stages of the replication cycle (1).  Late in the infectious cycle, 102 
the E4 protein may also act to diminish the integrity of the keratinocyte by disrupting the 
keratin cytoskeleton and cornified envelope formation, and inducing apoptosis through 104 
alteration of mitochondria function, to facilitate egress of the newly formed HPV virions 
(3, 6, 24, 26). 106 
Execution of multiple functions might be assisted by conversion of the E4 protein into 
multiple forms, brought about by a combination of sequential N-terminal proteolysis of the 108 
E1^E4 polypeptide (7, 25) and by phosphorylation (9, 21).  Indeed, a study of the 
interaction between E4 and cell growth revealed an interesting relationship between 110 
modification of the HPV1 E4 protein and dysregulation of the cell cycle (13).  During the 
HPV1 infectious cycle N-terminal sequences are removed from the full-length 17-kDa 112 
E1^E4 polypeptide to produce smaller E4 species of 16-, 11- and 10-kDa that 
progressively replace the full-length protein as the replication cycle proceeds (7, 25).  114 
Expression of the 17-kDa E1^E4 protein in the presence of a protein mimicking the 16-
kDa polypeptide in epithelial cells inhibits G2-to-M transition of the cell cycle and, in a 116 
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population of cells, prohibition of entry into S phase is also observed (13).  The negative 
effect on S phase entry however, was not apparent in cells expressing the individual forms 118 
of E4, although expression of the truncated 16-kDa protein alone was sufficient to block 
cell division (13).  Further analysis revealed that HPV1 E4 employed two distinct 120 
mechanisms to inhibit G2-to-M transition, the first, mediated by the combined expression 
of 17- and 16-kDa proteins, was found to be dependent on maintenance of high levels of 122 
the Wee1 kinase to inhibit cdk1 activity, and the second, mediated by the 16-kDa protein, 
was associated with insufficient production of cyclin B1 to enable the cells to transverse 124 
G2 to M (13, 14).  Employment of two distinct mechanisms to inhibit cell division 
suggests that the G2 arrest function of HPV1 E4 is important in the HPV life cycle.  In this 126 
study we investigated how HPV1 E4 inhibits progression of cells into S phase and show 
that HPV1 E4 affects a key step in the cellular DNA replication process. 128 
Materials and methods 
HPV1 E4 expression plasmids 130 
Construction of plasmids based on pcDNA3.1 that deliver expression of the 17-kDa full-
length HPV1 E1^E4 (E4-17K) and an N-terminal truncation (E4-16K) equivalent to the 132 
16-kDa E4 polypeptide have been described previously (29).  A set of previously described 
deletions within the full-length E1^E4 coding sequence (25) were excised and inserted into 134 
the BamHI restriction site of pcDNA3.1 (Invitrogen, Carlsbad, CA).  The sequence 
integrity of plasmid inserts was verified by bi-directional DNA sequencing.  Substitutions 136 
E4R45A, E4R47A and E4R48A are described elsewhere (1). 
Expression of recombinant proteins 138 
HPV1 E4 and Xenopus laevis Cdc6 (His6-XeCdc6) proteins were purified from Sf9 insect 
cells following infection with appropriate recombinant baculoviruses, as previously 140 
described (28, 31).  Histidine-tagged human geminin (His6-hsGeminin) was expressed in 
Escherichia coli and purified as described (36).  For expression of histidine-tagged HPV1 142 
E4 protein in bacteria, the E1^E4 wild type and mutant coding sequences were inserted 
into the BamHI – EcoRI cloning site of the expression vector pRSET-C (Invitrogen) and 144 
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expressed in E. coli strain BL21 (DE3) pLysS (Novagen, Madison, WI, USA).  The 
recombinant protein was purified by IMAC using NiCl2-charged HiTRAP chelating 146 
columns (GE Healthcare Europe GmbH, Munich, Germany).  Non-specifically bound 
proteins were removed with 4 column volumes (c.v.) of 10% elution buffer (30 mM Tris-148 
Cl pH 8, 300 mM imidazole, 30 mM NaCl, 0.1 mM PMSF) and 8 c.v. of 20% elution 
buffer.  The E4 proteins were eluted with 2 c.v. of 100% elution buffer and desalted into 150 
20 mM Tris-Cl pH 8, 50 mM NaCl. 
In vitro cellular DNA replication assays 152 
Nuclei and cytosolic extracts were prepared from synchronized NIH3T3 and HeLa S3 cells 
and supplemented as described previously (11, 15, 31, 32).  In vitro DNA replication 154 
assays were performed as described (15, 31) (Fig. 1A).  Briefly, reactions contained 30 !l 
of cytosolic extracts (250-300 !g of protein), 10 !l of premix buffer (160 mM K-HEPES 156 
pH 7.8, 28 mM MgCl2, 12 mM ATP, 0.4 mM of GTP, CTP, UTP, dATP, dGTP and dCTP, 
1 !M biotin-16-dUTP, 2 mM dithiothreitol, 160 mM creatine phosphate, 20 !g 158 
phosphocreatine kinase), 1 x 10
5
 nuclei and, where indicated, up to 10 !l of recombinant 
protein(s).  His6-XeCdc6 protein in 20 mM HEPES pH 7.4, 150 mM NaCl, 5% glycerol, 1 160 
mM DTT was added to in vitro replication reactions at a final concentration of 0.65 µM, 
baculovirus-expressed HPV1 E4 proteins in 10 mM phosphate buffer pH 7.4, 0.1 mM DTT 162 
at 3 µM, bacterially-expressed His6-E4 proteins in 40 mM Tris-HCl pH 7.6, 30 mM NaCl, 
and His6-hsGeminin protein in 50 mM Na-phosphate at 4 µM.  Equal volumes of 164 
appropriate buffers were added to control reactions.  All components of the replication 
reactions were incubated together on ice for 15 min prior to the addition of S phase cytosol 166 
and incubation for 3 h at 37°C.  For analysis of in vitro DNA synthesis reactions by 
confocal microscopy, reactions were stopped by diluting with 500 !l of phosphate-168 
buffered saline (PBS) and nuclei fixed for 5 min in 4% paraformaldehyde.  After fixation, 
nuclei were spun through a 30% sucrose/PBS cushion onto poly-L-lysine coated 170 
coverslips.  All subsequent washing and staining steps were carried out in PBS, 0.2% 
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Triton X-100, 0.04% SDS.  Coverslips were washed, stained for incorporated biotin-16-172 
dUTP with fluorescein-linked streptavidin (1:100 dilution, Amersham) and for DNA with 
propidium iodide/RNase A (both at 50 ng/ml), washed again, and mounted in Vectorshield. 174 
Confocal fluorescence microscopy of random fields of nuclei was performed on a Leica 
TCS DMRE confocal microscope and the number of nuclei incorporating biotin-16-dUTP 176 
in vitro and non-replicating nuclei were counted.  Routinely 800-1000 nuclei were scored 
blind by a single individual for each reaction and quantitated as percentages of the total 178 
number of nuclei that synthesized DNA in vitro.  More than one preparation of nuclei was 
assayed, in triplicate, for each set of experiments and analysis performed by two 180 
individuals.  Statistical analysis of data from multiple independent experiments was 
performed by single factor analysis of variance (ANOVA). 182 
Chromatin-binding assay 
In vitro DNA replication assays were set up as described above.  After 3 h incubation, 184 
nuclei were pelleted by low speed (1300xg) centrifugation and used in chromatin-binding 
reactions performed as described previously (12).  Samples were immunoblotted with 186 
antibodies against Mcm2 (BD Biosciences, #610701), Mcm7 (Neomarkers, Lab Vision, 
Suffolk, UK, #MS-862-P), Cdc6 (Santa Cruz, CA, USA, #9964), HPV1 E4 (MAb 4.37, 188 
(7)) and Histone H1 (Santa Cruz, CA, #10806).  Analysis of protein bands using 
densitometry was determined using ImageJ (http://rsb.info.nih.gov/ij).  Chromatin-binding 190 
reactions were repeated at least twice in separate in vitro DNA replication assays. 
Cell transfection and cell cycle analysis 192 
Cos-1 cells were transfected with the appropriate combinations of HPV1 E4 expression 
plasmids, or the pcDNA3.1 empty vector as a control plasmid, as described previously 194 
(13).  At 48 h post-transfection, the cells were incubated with 5-bromodeoxyuridine 
(BrdU) at a final concentration of 33 µM for 2 h.  Cells were then fixed, incubated with an 196 
anti-BrdU antibody conjugated to fluorescein isothiocyanate, labelled with propidium 
ACC
EPT
ED
 o
n
 D
ecem
ber 21, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
HPV E4 inhibits cellular DNA synthesis 
8 
iodide and analysed by dual-parameter flow cytometry as described (13).  Statistical 198 
analysis of data derived from multiple independent experiments was performed by 
ANOVA.  Expression of E4 proteins was confirmed by immunoblot analysis using an 200 
HPV1 E4 monoclonal antibody (MAb 4.37). 
Results 202 
HPV1 E4 inhibits cellular DNA replication in vitro 
We sought to establish whether the negative effect of HPV1 E4 upon S phase entry 204 
reflected an interaction between the viral protein and the process of cellular DNA synthesis 
itself.  To do this, we took advantage of an established cell-free DNA replication system 206 
that supports efficient cellular DNA synthesis under somatic cell cycle control (31) (Fig. 
1A). Previous characterisation of this system revealed that nuclei prepared from quiescent 208 
(G0) NIH3T3 fibroblasts cannot initiate DNA synthesis in S phase cytosolic extracts of 
HeLa cells, whilst G1 nuclei become competent to initiate DNA replication in the S phase 210 
extracts when prepared 16 to 18 hours after release from G0 (31).   
NIH3T3 G1 nuclei were combined with HeLa S phase cytosol and incubated for 3 h in the 212 
presence of an ATP generation system and nucleotides (NTPs and dNTPs) including 
biotin-labelled dUTP as a marker to enable detection of DNA synthesis by confocal 214 
microscopy (Fig. 1A).  We observed that 19.3% of G1 nuclei were capable of DNA 
synthesis in the presence of S phase cytosol in comparison to only 2.2% following 216 
incubation of the G1 nuclei in a physiological buffer (Buffer A) that supports elongation 
but not initiation of DNA replication (Fig. 1C).  The small proportion of replication 218 
competent nuclei observed in Buffer A represent contaminating S phase nuclei present in 
the G1 nuclear preparation that continue DNA synthesis at replication forks established in 220 
vivo prior to their isolation (31).  Thus, 17.1% of G1 nuclei undergo true replication 
initiation in the presence of S phase cytosol.  To confirm that our preparations of G1 nuclei 222 
and S phase cytosol respond to exogenous factors, we first tested the response to 
recombinant preparations of the replication-licensing factor (RLF) Cdc6 (His6-XeCdc6) 224 
and geminin (His6-hsGeminin), a known cellular repressor of replication licensing (18).  
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The percentage of replicating nuclei increased from 19.3% to 23% in reactions containing 226 
His6-XeCdc6 (Fig. 1C).  Since Cdc6 is known to be rate-limiting for replication 
competence after release from G0 (31), the small but consistent increase in replicating 228 
nuclei in the presence of His6-XeCdc6 indicates a low number of G1 nuclei are responsive 
to this RLF.  In contrast, in the presence of His6-hsGeminin there was a marked and 230 
significant decrease (7.2%) in the percentage of replication competent nuclei (Fig. 1C). 
To investigate if HPV1 E4 might interfere with cellular DNA synthesis, the viral protein 232 
was expressed in Sf9 insect cells using a recombinant baculovirus and the purified protein 
(Fig. 1B, WT38) titrated into in vitro replication reactions (Fig. 1C).  Whilst we observed 234 
no significant effect of E4 on the percentage of nuclei synthesizing DNA in co-incubations 
of G1 nuclei and S phase cytosol (19.7%), when E4 was added to reactions that also 236 
contain exogenous Cdc6 (His6-XeCdc6), the percentage of replicating nuclei decreased 
significantly from 23% to 10.6%, indicating that 54% of the replication-competent nuclei 238 
failed to initiate DNA synthesis (Fig. 1C).  Notably, the scale of E4-induced replication 
inhibition was comparable to the inhibitory effect (67%) of His6-hsGeminin (Fig. 1C). 240 
The E4 protein added to the in vitro replication assays contained the full-length E1^E4 
protein (17-kDa) plus small quantities of truncated polypeptides (16-, 11-, and 10-kDa) 242 
(Fig. 1B, WT38).  Interestingly, addition of recombinant E4 protein that contains the 
truncated proteins, but no full-length E1^E4 polypeptide (Fig. 1B, WT43) to the cell-free 244 
replication assay did not inhibit DNA synthesis in the G1 nuclei either in the absence (data 
not shown) or presence of exogenous Cdc6 (Fig. 1C, !E4).  This observation suggests that 246 
E4-induced inhibition of cellular DNA synthesis in vitro requires the presence of the full 
length E1^E4 protein. 248 
To validate the specificity of our findings, identical replication reactions to those described 
above, but using a separate preparation of baculovirus-expressed E4 protein containing a 250 
similar profile of E4 species to WT38, and G1 nuclei prepared from human WI38 diploid 
fibroblasts, achieved a similar level of replication inhibition (55%; data not shown). 252 
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HPV1 E4 does not arrest ongoing cellular DNA synthesis in vitro 
Unlike G1 nuclei, nuclei isolated from cells in the S phase of the cell cycle contain active 254 
replication forks and are thus competent for DNA synthesis in the absence of cytosolic S 
phase extracts (31).  Addition of geminin, an inhibitor of origin licensing, to in vitro 256 
replication reactions containing NIH3T3 S phase nuclei as the source of template failed to 
affect ongoing DNA synthesis (Fig. 1D) consistent with previous reports (18, 33, 40).  258 
Significantly, cellular DNA elongation was also not affected by the addition of 
recombinant E4 protein (WT38) to S phase nuclei, either in the absence or presence of 260 
His6-XeCdc6 (Fig. 1D).  The data from the in vitro replication assay (Fig. 1) indicate that 
in the presence of exogenous Cdc6, HPV1 E4 inhibits initiation of DNA synthesis, but 262 
fails to arrest ongoing DNA synthesis. 
HPV1 E4 blocks recruitment of replication licensing proteins onto chromatin in vitro 264 
Initiation of cellular DNA replication is achieved by the ordered assembly of pre-
replicative complexes (pre-RCs) at origins of replication (34).  During late mitosis (M) and 266 
early G1 phase, RLFs Cdc6 and Cdt1, by interacting with the origin recognition complex, 
load the putative DNA replicative helicase Mcm2-7 onto chromatin to form pre-RCs.  In 268 
the subsequent S phase, DNA replication is initiated at these “licensed” origins by the 
concerted action of cyclin dependent kinases and Cdc7-Dbf4.  To investigate whether 270 
HPV1 E4 might inhibit replication initiation by blocking assembly of pre-RCs onto 
chromatin, we resolved chromatin-bound protein fractions prepared from G1 and S phase 272 
nuclei taken through in vitro replication reactions by gel electrophoresis and probed for 
RLFs Cdc6, Mcm2 and Mcm7 (Fig. 2).  Histone H1 levels were used as a loading control.  274 
Chromatin prepared from G1 nuclei incubated with S phase cytosol showed a two-fold 
increase in the binding of endogenous Cdc6 and MCM factors compared to the elongation 276 
control reaction (Buffer A) (Fig. 2A).  Addition of recombinant Cdc6 to replication 
reactions led to a 1.5-fold increase in the total amount of chromatin-bound Cdc6 and 278 
further increased levels of chromatin-bound MCMs (Fig. 2A), correlating with the 
observed small increase in the percentage of replication-competent nuclei (Fig. 1C).  In 280 
contrast, geminin inhibited origin licensing by blocking loading of Mcm2 onto chromatin 
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(Fig. 2A), indicating that increased levels of chromatin-bound RLFs in nuclei taken 282 
through the replication assay are a result of genuine pre-RC assembly in vitro.  Addition of 
HPV1 E4 protein (WT38) with His6-XeCdc6 to the replication reactions was associated 284 
with a 3.5-fold and 2-fold decrease in chromatin-bound Mcm2 and Mcm7 proteins 
respectively, compared to reactions containing His6-XeCdc6 alone (Fig. 2A).  Notably, the 286 
reduced levels of chromatin-bound MCM proteins were close to base levels measured in 
G1 nuclei incubated with Buffer A (Fig. 2A).  The reduction of chromatin-bound MCM 288 
proteins by the HPV1 protein correlated with its ability to inhibit replication, as Mcm2 and 
Mcm7 levels were not affected by addition of E4 in the absence of exogenous Cdc6, or by 290 
the addition of E4 protein lacking full-length E1^E4 protein (!E4) to reactions containing 
His6-XeCdc6 (Fig. 2A).  There was no evidence that E4 became bound to chromatin, either 292 
in the presence or absence of exogenous Cdc6 (see Fig. 4b). 
Chromatin-binding studies on S phase nuclei taken through replication elongation assays 294 
show that neither addition of geminin nor E4 together with His6-XeCdc6 affected the 
chromatin-binding status of Mcm2 and Mcm7 (Fig. 2B). 296 
Together, the in vitro replication and chromatin-binding data indicate that inhibition of 
initiation of cellular DNA synthesis by HPV1 E4 in the presence of His6-XeCdc6 correlates 298 
with reduced MCM loading onto chromatin.   
Repression of S phase entry by HPV1 E4 in epithelial cells is dependent on an 300 
arginine-rich motif in the E1^E4 protein 
To determine whether there is a relationship between the negative effect of HPV1 E4 on 302 
cell proliferation (13) and E4’s ability to inhibit cellular DNA replication in vitro, we first 
identified the HPV1 E1^E4 sequences required for suppression of S phase entry in 304 
epithelial cells.  Since the negative effect of HPV1 E1^E4 on S phase entry was dependent 
on the presence of a truncated 16-kDa E4 protein (13), HPV1 E1^E4 (E4-17K) expression 306 
plasmids containing small deletions that cover the majority of the E1^E4 sequence, were 
individually co-transfected with the plasmid expressing the truncated protein (E4-16K) 308 
into Cos epithelial cells, and cellular DNA synthesis monitored by BrdU incorporation.  In 
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keeping with our previous findings (13), transient expression of the full-length E1^E4 310 
protein together with E4-16K reduced S phase BrdU incorporation by nearly 2-fold, in 
comparison to cells expressing the individual proteins, or control cells (Table 1).  Of the 312 
E1^E4 deletion plasmids tested, only one, containing a deletion of residues 44 to 48 
(GRPRR), did not inhibit S phase entry following co-transfection with E4-16K (Table 1).  314 
The G2 arrest function of this mutant E1^E4 protein however remained intact (data not 
shown).  316 
The contribution of individual amino acids within the 44GRPRR48 sequence to E1^E4 
function was examined by substituting the arginine residues at positions 45, 47 and 48 by 318 
alanine residues (E4R45A, E4R47A, E4R48A).  Following co-transfection of these mutant 
E1^E4 plasmids with the E4-16K expression plasmid into Cos cells, BrdU incorporation 320 
revealed that inhibition of entry into S phase was sensitive to alanine substitution of Arg45, 
but not mutation of Arg47 or Arg48 (Fig. 3A).  Loss of inhibitory action was not due to 322 
any change in the stability of the E4R45A E1^E4 protein in epithelial cells (Fig. 3B), and 
all three mutants promoted G2 arrest to levels comparable with E4-17/16K expressing cells 324 
(data not shown). 
The arginine-rich motif in E1^E4 is necessary for inhibition of cellular DNA synthesis 326 
initiation in vitro 
Next, we wanted to determine whether the 44GRPRR48 sequence E1^E4 was also involved 328 
in inhibition of cellular origin licensing in the in vitro replication assay.  In this instance, 
the recombinant HPV1 E4 proteins were expressed and purified from bacteria.  To verify 330 
that a bacterial form of the E4 protein encodes an inhibitory function, the wild-type protein 
was titrated into the in vitro replication reactions.  Consistent with the data using 332 
baculovirus recombinant E4 protein, we observed no significant effect of E4 on the 
percentage of nuclei synthesizing DNA following addition of the bacterial E4 protein to 334 
co-incubations of NIH3T3 G1 nuclei and HeLa S phase cytosol (24%, Fig. 4A).  However 
when E4 was added to reactions that also contain exogenous Cdc6 (His6-XeCdc6), the 336 
percentage of replicating nuclei decreased significantly from 29% to 13.8%, indicating that 
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in the presence of a bacterial derived HPV1 E4 protein nearly 53% of the replication-338 
competent nuclei failed to initiate DNA synthesis (Fig. 4A).  Inhibition of cellular 
replication initiation was however abrogated upon the addition of the E4 protein containing 340 
deletion of 44GRPRR48 to the in vitro reactions containing His6-XeCdc6 (26.5%, Fig. 4A), 
and alanine substitution of arginine 45 (E4R45A) within this motif was sufficient to relieve 342 
the inhibitory effect of the HPV protein (23.2%, Fig. 4A). 
Our analysis of pre-RC assembly in the in vitro replication assay had indicated that HPV1 344 
E4 protein inhibited loading of MCM onto chromatin (Fig. 2).  Therefore we investigated 
whether failure to inhibit replication initiation by the mutant E1^E4 proteins correlated 346 
with efficient assembly of pre-RCs onto chromatin.  Chromatin-bound protein fractions 
prepared from G1 and S phase nuclei taken through in vitro replication reactions were 348 
probed for RLFs Cdc6, and MCM proteins 2 and 7 (Fig. 4B).  Chromatin prepared from 
G1 nuclei incubated with S phase cytosol in the presence of His6-XeCdc6 and the wild-type 350 
protein derived from bacteria showed a 51% and 41% decrease in chromatin-bound Mcm2 
and Mcm7 proteins respectively, compared to the level of these proteins in the reaction 352 
containing His6-XeCdc6 alone (Fig. 4B).  The reduced levels of chromatin-bound MCM 
proteins in the presence of the bacterial preparation of E4 were similar to the decrease 354 
observed with the baculovirus-recombinant E4 protein (Fig. 2).  However, in the presence 
of mutant E1^E4 proteins E4!44-48 and E4R45A both Mcm2 and Mcm7 were efficiently 356 
recruited to chromatin (Fig. 4B). 
Together, our data suggest that HPV1 E4 inhibits initiation of cellular DNA replication in 358 
vitro by blocking MCM loading onto chromatin and that this is dependent on an arginine-
rich motif within the full-length form of the viral protein.  360 
Discussion 
Using a cell-free cellular DNA replication assay, we have shown that HPV1 E4 protein is a 362 
potent inhibitor of cellular replication licensing; a novel function for this protein.  
Chromatin binding studies indicate that E4 blocks replication initiation in vitro by 364 
preventing loading of licensing factors Mcm2 and Mcm7 onto chromatin.  The functional 
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effect of E4 mimics the cellular repressor of replication licensing geminin (18), but while 366 
geminin interacts with the RLF Cdt1 to inhibit assembly of MCMs into pre-RCs, the 
mechanism by which E4 blocks MCM loading appears different to that of the cellular 368 
repressor.  Unlike geminin, inhibition of licensing in vitro by E4, requires addition of an 
exogenous supply of soluble Cdc6.  The requirement for exogenous Cdc6 for E4 mediated 370 
inhibition of DNA replication may be explained by the differential regulation of Cdc6 in 
normal proliferating cells, where Cdc6 is found in both the soluble and chromatin-bound 372 
fractions (30) and during the G0-S transition, where Cdc6 is synthesised de novo and 
immediately recruited to replication origins (12).  In the in vitro replication assay used in 374 
this study, NIH3T3 G1 nuclei are prepared during release from density-dependent growth 
arrest (G0) and therefore contain only chromatin-bound Cdc6 protein (31).  How HPV1 E4 376 
and the soluble form of the licensing factor Cdc6 function together to inhibit replication is 
not yet understood, but they are sufficient to block MCM recruitment to origins even in the 378 
presence of chromatin bound Cdc6.  One possibility is that E4 is able to complex with 
MCM factors in a soluble Cdc6-dependent manner.  We have evidence of an association 380 
between a GST-HPV1 E1^E4 fusion protein and an epitope-tagged form of Mcm7 
expressed in cell lysates containing soluble Cdc6 (I. Bell and Sally Roberts, preliminary 382 
data).  Association between E1^E4 and this MCM factor however, might not be a complete 
description of the mechanism of E4-mediated replication inhibition since !E4, the form of 384 
HPV1 E4 defective in inhibiting cellular DNA synthesis, can form an association with 
Mcm7 (I. Ashmole and S. Roberts, unpublished data).  It is feasible that further 386 
modification, for example a phosphorylation event, is necessary to achieve an “active” 
inhibitory complex and this might be dependent on N-terminal sequences specific to the 388 
full-length E1^E4 polypeptide.  Whatever the underlying mechanism, inhibition of 
initiation of cellular DNA replication in vitro and suppression of entry of epithelial cells 390 
into S phase are functions both dependent on arginine 45 in the HPV1 E1^E4 polypeptide, 
suggesting that these two functions are linked and hence implies that E4 can block cellular 392 
DNA synthesis in the presence of endogenous soluble Cdc6. 
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Our studies have shown that E4-induced inhibition of in vitro replication initiation is 394 
dependent on a full-length E1^E4 molecule.  It is possible that the smaller forms of E4 that 
exist in the purified preparations of HPV1 E4 protein used in this study may contribute to 396 
this E1^E4 function.  Indeed HPV1 E4 expression studies show that co-expression of full-
length and truncated forms of HPV1 E4 act to repress cell proliferation, whilst expression 398 
of the full-length form alone did not (13).  Complex formation between the different E4 
polypeptides (14) might be one explanation, either the complex inhibiting S phase entry 400 
directly or, upon formation, depleting free full-length protein to a level that it is then active 
with regards to blocking cell proliferation.  This latter explanation might well explain why 402 
there is no block in cell proliferation in cells expressing the E1^E4 protein alone even 
though a small amount of the truncated E4 species does accumulate in these cells.   404 
We do not know at this stage of our investigations whether this novel HPV1 E4 function is 
conserved between the different phylogenetic types.  Arginine 45 lies in a region of HPV1 406 
E4 that is rich in basic amino acids and indeed similar (but not identical) regions are to be 
found in E4 proteins of types with a dissimilar tropism to HPV1, such as HPV16 and 18 408 
that have preference for epithelia of the oral and anogenital tracts (1).  The basic region of 
HPV16 E4 forms part of the G2 arrest domain (5), but in HPV1 E4 is not a required 410 
element of the G2 arrest function, and nor do these regions contribute to the interaction 
with the keratin cytoskeleton (25, 27).  An association between HPV1 E4 and the SR 412 
protein kinase SRPK1 is dependent on arginine 45 (1), although other sequences required 
to maintain this interaction do not contribute to inhibition of cell proliferation, suggesting 414 
that this E4 binding partner is unlikely to be involved in the underlying mechanism of 
replication inhibition by HPV1 E4.  Therefore, either arginine 45 mediates an association 416 
to a novel E4-binding protein, or dictates a specific cellular localization, necessary for 
replication inhibition.  418 
Host cell DNA synthesis is blocked during Epstein-Barr virus (EBV) lytic infection cycle 
during which there is high level amplification of the EBV genome (17).  EBV inactivates 420 
MCM helicase function by phosphorylation of MCM proteins and this might be sufficient 
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to block cellular DNA synthesis in lytic infected cells (16).  Infection by another DNA 422 
virus, cytomegalovirus (CMV) also abrogates cellular replication licensing by inhibiting 
chromatin loading of MCM proteins (2, 37).  Even though the underlying mechanism of 424 
repression of cellular DNA replication by EBV and CMV were not identified, taken 
together with our study, it implies that unrelated DNA viruses may have evolved similar 426 
strategies to selectively inhibit host cell DNA synthesis.  This function could prove 
advantageous to viruses that depend on the host cell for the supply of essential replication 428 
enzymes and nucleotides for viral DNA synthesis.  Papillomaviruses have three phases of 
replication; establishment and maintenance of the genome in basal cells is followed by 430 
vegetative genome amplification in cells that have migrated up from the basal layer and 
differentiated (10).  Because keratinocyte differentiation normally correlates with exit from 432 
the cell cycle, the virus induces S phase gene activity in these cells, and eventually they 
initiate vegetative viral genome replication, whereby the viral genome is amplified to high 434 
copy number (4).  Notably, the switch to genome amplification is associated with induction 
of E4 protein (23).  Furthermore, more recently, it has been shown that this switch also 436 
correlates with suppression of cellular DNA synthesis in replication-activated HPV16-
containing keratinocytes (20).  We therefore hypothesize that in these cells, E4 acts to 438 
preserve the supply of essential host replication factors by inhibiting licensing of cellular 
origins of replication and thus repress competing cellular DNA synthesis.  Combined with 440 
action on G2-to-M transition of the cell cycle (5, 13, 19), E4 could be a key player in 
ensuring successful replication of the virus.  Indeed, loss of expression of the full-length 442 
E1^E4 protein is associated with an abrogation of efficient vegetative genome replication 
in systems that recapitulate the productive replication life cycles of HPV16, 18 and 31 and 444 
cottontail papillomavirus (20, 22, 38, 39). 
Viral factors such as E4 could provide powerful molecular tools that can be utilized to 446 
dissect the molecular mechanisms regulating initiation of eukaryotic DNA replication.  
Furthermore, because the origin licensing machinery has been proposed as a novel 448 
attractive target for anti-cancer therapy, the design of E4-based mimetic compounds could 
provide novel non genotoxic agents. 450 
ACC
EPT
ED
 o
n
 D
ecem
ber 21, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
HPV E4 inhibits cellular DNA synthesis 
17 
Acknowledgements 
We thank Ron Laskey for insightful discussions during the early stages of the project.  We 452 
are grateful to Renos Savva for help producing bacterial E1^E4 proteins and to Emma 
Yates for technical assistance.  This work was supported by Cancer Research UK 454 
Programme grants to SR (C427/A3919) and GHW/KS (C428/A2281).  SRK was 
supported by a Medical Research Council studentship. 456 
References 
1. Bell, I., A. Martin, and S. Roberts. 2007. The E1^E4 protein of human 458 
papillomavirus interacts with the serine-arginine-specific protein kinase SRPK1. J 
Virol 81:5437-48. 460 
2. Biswas, N., V. Sanchez, and D. H. Spector. 2003. Human cytomegalovirus 
infection leads to accumulation of geminin and inhibition of the licensing of 462 
cellular DNA replication. J Virol 77:2369-76. 
3. Bryan, J. T., and D. R. Brown. 2000. Association of the human papillomavirus 464 
type 11 E1^E4 protein with cornified cell envelopes derived from infected genital 
epithelium. Virology 277:262-9. 466 
4. Cheng, S., D. C. Schmidt-Grimminger, T. Murant, T. R. Broker, and L. T. 
Chow. 1995. Differentiation-dependent up-regulation of the human papillomavirus 468 
E7 gene reactivates cellular DNA replication in suprabasal differentiated 
keratinocytes. Genes Dev 9:2335-49. 470 
5. Davy, C. E., D. J. Jackson, Q. Wang, K. Raj, P. J. Masterson, N. F. Fenner, S. 
Southern, S. Cuthill, J. B. Millar, and J. Doorbar. 2002. Identification of a G(2) 472 
arrest domain in the E1^E4 protein of human papillomavirus type 16. J Virol 
76:9806-18. 474 
A
CEP
TED
 o
n
 D
ecem
ber 21, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
HPV E4 inhibits cellular DNA synthesis 
18 
6. Doorbar, J., S. Ely, J. Sterling, C. McLean, and L. Crawford. 1991. Specific 
interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the 476 
epithelial cell intermediate filament network. Nature 352:824-7. 
7. Doorbar, J., H. S. Evans, I. Coneron, L. V. Crawford, and P. H. Gallimore. 478 
1988. Analysis of HPV-1 E4 gene expression using epitope-defined antibodies. 
Embo J 7:825-33. 480 
8. Everett, R. D., and M. K. Chelbi-Alix. 2007. PML and PML nuclear bodies: 
implications in antiviral defence. Biochimie 89:819-30. 482 
9. Grand, R. J., J. Doorbar, K. J. Smith, I. Coneron, and P. H. Gallimore. 1989. 
Phosphorylation of the human papillomavirus type 1 E4 proteins in vivo and in 484 
vitro. Virology 170:201-13. 
10. Hebner, C. M., and L. A. Laimins. 2006. Human papillomaviruses: basic 486 
mechanisms of pathogenesis and oncogenicity. Rev Med Virol 16:83-97. 
11. Heintz, N. H., and B. W. Stillman. 1988. Nuclear DNA synthesis in vitro is 488 
mediated via stable replication forks assembled in a temporally specific fashion in 
vivo. Mol Cell Biol 8:1923-31. 490 
12. Kingsbury, S. R., M. Loddo, T. Fanshawe, E. C. Obermann, A. T. Prevost, K. 
Stoeber, and G. H. Williams. 2005. Repression of DNA replication licensing in 492 
quiescence is independent of geminin and may define the cell cycle state of 
progenitor cells. Exp Cell Res 309:56-67. 494 
13. Knight, G. L., J. R. Grainger, P. H. Gallimore, and S. Roberts. 2004. 
Cooperation between different forms of the human papillomavirus type 1 E4 496 
protein to block cell cycle progression and cellular DNA synthesis. J Virol 
78:13920-33. 498 
ACC
EPT
ED
 o
n
 D
ecem
ber 21, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
HPV E4 inhibits cellular DNA synthesis 
19 
14. Knight, G. L., A. S. Turnell, and S. Roberts. 2006. Role for Wee1 in inhibition 
of G2-to-M transition through the cooperation of distinct human papillomavirus 500 
type 1 E4 proteins. J Virol 80:7416-26. 
15. Krude, T., M. Jackman, J. Pines, and R. A. Laskey. 1997. Cyclin/Cdk-502 
dependent initiation of DNA replication in a human cell-free system. Cell 88:109-
19. 504 
16. Kudoh, A., T. Daikoku, Y. Ishimi, Y. Kawaguchi, N. Shirata, S. Iwahori, H. 
Isomura, and T. Tsurumi. 2006. Phosphorylation of MCM4 at sites inactivating 506 
DNA helicase activity of the MCM4-MCM6-MCM7 complex during Epstein-Barr 
virus productive replication. J Virol 80:10064-72. 508 
17. Kudoh, A., M. Fujita, T. Kiyono, K. Kuzushima, Y. Sugaya, S. Izuta, Y. 
Nishiyama, and T. Tsurumi. 2003. Reactivation of lytic replication from B cells 510 
latently infected with Epstein-Barr virus occurs with high S-phase cyclin-dependent 
kinase activity while inhibiting cellular DNA replication. J Virol 77:851-61. 512 
18. McGarry, T. J., and M. W. Kirschner. 1998. Geminin, an inhibitor of DNA 
replication, is degraded during mitosis. Cell 93:1043-53. 514 
19. Nakahara, T., A. Nishimura, M. Tanaka, T. Ueno, A. Ishimoto, and H. Sakai. 
2002. Modulation of the cell division cycle by human papillomavirus type 18 E4. J 516 
Virol 76:10914-20. 
20. Nakahara, T., W. L. Peh, J. Doorbar, D. Lee, and P. F. Lambert. 2005. Human 518 
papillomavirus type 16 E1^E4 contributes to multiple facets of the papillomavirus 
life cycle. J Virol 79:13150-65. 520 
21. Nasseri, M., R. Hirochika, T. R. Broker, and L. T. Chow. 1987. A human 
papilloma virus type 11 transcript encoding an E1--E4 protein. Virology 159:433-522 
9. 
ACC
EPT
D
 o
n
 D
ecem
ber 21, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
HPV E4 inhibits cellular DNA synthesis 
20 
22. Peh, W. L., J. L. Brandsma, N. D. Christensen, N. M. Cladel, X. Wu, and J. 524 
Doorbar. 2004. The viral E4 protein is required for the completion of the cottontail 
rabbit papillomavirus productive cycle in vivo. J Virol 78:2142-51. 526 
23. Peh, W. L., K. Middleton, N. Christensen, P. Nicholls, K. Egawa, K. Sotlar, J. 
Brandsma, A. Percival, J. Lewis, W. J. Liu, and J. Doorbar. 2002. Life cycle 528 
heterogeneity in animal models of human papillomavirus-associated disease. J 
Virol 76:10401-16. 530 
24. Raj, K., S. Berguerand, S. Southern, J. Doorbar, and P. Beard. 2004. E1 empty 
set E4 protein of human papillomavirus type 16 associates with mitochondria. J 532 
Virol 78:7199-207. 
25. Roberts, S., I. Ashmole, L. J. Gibson, S. M. Rookes, G. J. Barton, and P. H. 534 
Gallimore. 1994. Mutational analysis of human papillomavirus E4 proteins: 
identification of structural features important in the formation of cytoplasmic 536 
E4/cytokeratin networks in epithelial cells. J Virol 68:6432-45. 
26. Roberts, S., I. Ashmole, G. D. Johnson, J. W. Kreider, and P. H. Gallimore. 538 
1993. Cutaneous and mucosal human papillomavirus E4 proteins form intermediate 
filament-like structures in epithelial cells. Virology 197:176-87. 540 
27. Roberts, S., I. Ashmole, S. M. Rookes, and P. H. Gallimore. 1997. Mutational 
analysis of the human papillomavirus type 16 E1--E4 protein shows that the C 542 
terminus is dispensable for keratin cytoskeleton association but is involved in 
inducing disruption of the keratin filaments. J Virol 71:3554-62. 544 
28. Roberts, S., I. Ashmole, T. M. Sheehan, A. H. Davies, and P. H. Gallimore. 
1994. Human papillomavirus type 1 E4 protein is a zinc-binding protein. Virology 546 
202:865-74. 
A
CEP
TED
 o
n
 D
ecem
ber 21, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
HPV E4 inhibits cellular DNA synthesis 
21 
29. Roberts, S., M. L. Hillman, G. L. Knight, and P. H. Gallimore. 2003. The ND10 548 
component promyelocytic leukemia protein relocates to human papillomavirus type 
1 E4 intranuclear inclusion bodies in cultured keratinocytes and in warts. J Virol 550 
77:673-84. 
30. Saha, P., J. Chen, K. C. Thome, S. J. Lawlis, Z. H. Hou, M. Hendricks, J. D. 552 
Parvin, and A. Dutta. 1998. Human CDC6/Cdc18 associates with Orc1 and 
cyclin-cdk and is selectively eliminated from the nucleus at the onset of S phase. 554 
Mol Cell Biol 18:2758-67. 
31. Stoeber, K., A. D. Mills, Y. Kubota, T. Krude, P. Romanowski, K. 556 
Marheineke, R. A. Laskey, and G. H. Williams. 1998. Cdc6 protein causes 
premature entry into S phase in a mammalian cell-free system. Embo J 17:7219-29. 558 
32. Stoeber, K., T. D. Tlsty, L. Happerfield, G. A. Thomas, S. Romanov, L. 
Bobrow, E. D. Williams, and G. H. Williams. 2001. DNA replication licensing 560 
and human cell proliferation. J Cell Sci 114:2027-41. 
33. Tada, S., A. Li, D. Maiorano, M. Mechali, and J. J. Blow. 2001. Repression of 562 
origin assembly in metaphase depends on inhibition of RLF-B/Cdt1 by geminin. 
Nat Cell Biol 3:107-13. 564 
34. Takeda, D. Y., and A. Dutta. 2005. DNA replication and progression through S 
phase. Oncogene 24:2827-43. 566 
35. Walboomers, J. M., M. V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, 
K. V. Shah, P. J. Snijders, J. Peto, C. J. Meijer, and N. Munoz. 1999. Human 568 
papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 
189:12-9. 570 
ACC
EPT
ED
 o
n
 D
ecem
ber 21, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
HPV E4 inhibits cellular DNA synthesis 
22 
36. Wharton, S. B., S. Hibberd, K. L. Eward, D. Crimmins, D. A. Jellinek, D. 
Levy, K. Stoeber, and G. H. Williams. 2004. DNA replication licensing and cell 572 
cycle kinetics of oligodendroglial tumours. Br J Cancer 91:262-9. 
37. Wiebusch, L., R. Uecker, and C. Hagemeier. 2003. Human cytomegalovirus 574 
prevents replication licensing by inhibiting MCM loading onto chromatin. EMBO 
Rep 4:42-6. 576 
38. Wilson, R., F. Fehrmann, and L. A. Laimins. 2005. Role of the E1--E4 protein in 
the differentiation-dependent life cycle of human papillomavirus type 31. J Virol 578 
79:6732-40. 
39. Wilson, R., G. B. Ryan, G. L. Knight, L. A. Laimins, and S. Roberts. 2007. The 580 
full-length E1E4 protein of human papillomavirus type 18 modulates 
differentiation-dependent viral DNA amplification and late gene expression. 582 
Virology 362:453-60. 
40. Wohlschlegel, J. A., B. T. Dwyer, S. K. Dhar, C. Cvetic, J. C. Walter, and A. 584 
Dutta. 2000. Inhibition of eukaryotic DNA replication by geminin binding to Cdt1. 
Science 290:2309-12. 586 
 
 588 
ACC
EPT
ED
 o
n
 D
ecem
ber 21, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
HPV E4 inhibits cellular DNA synthesis 
23 
Figure legends 
Figure 1.  HPV1 E4 inhibits initiation of cellular DNA synthesis in an in vitro 590 
replication assay. (A) Cell-free cellular DNA replication system. Nuclei (N) 
prepared from G1 phase NIH3T3 fibroblasts, synchronized by release from 592 
quiescence (G0), initiate a single round of semi-conservative DNA replication in 
cytosolic extracts (SC) from S phase HeLa cells following incubation in buffer A 594 
(BA) that support elongation, nucleotides (dNTPs, NTPs) and an ATP regeneration 
system (CP, CK).  Nuclei are stained with propidium iodide to reveal DNA (red) 596 
and with fluorescein-streptavidin (green) to detect biotin-16-dUTP incorporation 
resulting from in vitro DNA synthesis. (B) Coomassie-stained SDS-PAGE gel of 598 
baculovirus recombinant HPV1 E4 proteins.  Lane 1, molecular weight standards 
(12.3-, 17.2-, 30-, 42.7-, 66-, 76-kDa); lanes 2 and 3, purified HPV1 E4 proteins 600 
WT38 and WT43 containing variable levels of full-length E1^E4 (17-kDa) and 
processed (16- and 11-kDa) species. (C) NIH3T3 G1 nuclei were incubated in 602 
cytosolic extracts from S phase HeLa cells, which induce initiation in competent 
nuclei, or in elongation buffer (Buffer A) which only supports elongation DNA 604 
synthesis in nuclei that are already in S phase.  Addition of E4 (but not !E4) and 
Cdc6 to co-incubations inhibits DNA synthesis at a level comparable to the effect 606 
of geminin.  Results are expressed as the percentage of nuclei replicating (mean ± 
standard deviation), and asterisks indicate a significance of >99.99% in the 608 
decrease of replicating nuclei compared to control replication assays.  (D) Addition 
of E4 and Cdc6 to co-incubations of NIH3T3 S phase nuclei and Hela S phase 610 
cytosol had no effect on replication potential.  Similarly, addition of geminin did 
not affect ongoing DNA synthesis.  Data analyzed as described in C. 612 
 
Figure 2.  HPV1 E4 suppresses recruitment of MCM proteins onto chromatin in vitro. 614 
Immunoblots of chromatin-bound protein fractions prepared from NIH3T3 G1 
phase (A) and S phase (B) nuclei taken through in vitro replication assays.  The 616 
densities of protein bands were determined and shown in the histograms relative to 
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those measured in nuclei incubated in S phase cytosol (SC), after normalization 618 
against histone H1 loading, 
 620 
Figure 3. Inhibition of S phase entry by HPV1 E4 in epithelial cells is dependent on 
an arginine residue within the E1^E4 protein.  Cos-1 epithelial cells were 622 
transfected with expression plasmids and pulse-labelled with BrdU, and the 
percentage of BrdU-positive S phase cells counted.  (A) Co-expression of full-624 
length E1^E4 with the truncated E4 protein E4-16K inhibits S phase entry 
compared to expression of the polypeptides alone.  Alanine replacement of arginine 626 
45 (R45A), but not of arginines 47 (R47A) or 48 (R48A), is sufficient to relieve the 
inhibitory effect upon S phase progression (mean ± standard deviation).  The 628 
double and single asterisk(s) indicates a significance of 99.99% and 99.98% 
respectively, in the decrease in the percentage of BrdU-positive cells compared to 630 
Cos cells transfected with empty vector.  The data shown was collected from seven 
independent experiments.  The two-dimensional BrdU-PI profiles of cells 632 
expressing E4-16K, E1^E4+E4-16K, R45A+E4-16K and R47A+E4-16K are as 
shown.  (B) Immunoblot of protein extracts showing E4 protein expression in Cos-634 
1 cells.  Migration of full-length (E1^E4) and truncated (E4-16K) polypeptides are 
as indicated. 636 
 
Figure 4. The arginine-rich motif in E1^E4 is necessary for inhibition of cellular DNA 638 
synthesis initiation in vitro.  (A) Addition of bacterial recombinant wildtype 
HPV1 E4 protein (WTE4) and Cdc6 to co-incubations of NIH3T3 G1 nuclei and 640 
HeLa S phase cytosol inhibits cellular DNA synthesis in replication competent 
nuclei.  E4-mediated inhibition is relieved following addition of mutant E4 proteins 642 
containing either a deletion of residues 44 to 48 (E4!44-48) or a single alanine 
replacement of arginine 45 (E4R45A), together with Cdc6.  Data from three 644 
independent experiments are given as the mean ± standard deviation, and a single 
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asterisk indicates a >99.99% significance in the decrease of replicating nuclei 646 
compared to control replication assay containing exogenous Cdc6. (B) Immunoblot 
of chromatin-bound protein fractions prepared from NIH3T3 G1 nuclei taken 648 
through in vitro replication reactions containing wild type and mutant E4 proteins.  
The histogram shows the densities of the protein bands, after normalization against 650 
histone H1 loading, relative to those in nuclei incubated in S phase cytosol (SC). 
 652 
 
 654 
 
 656 
 
 658 
 
 660 
 
 662 
 
 664 
 
 666 
 
 668 
 
 670 
 
 672 
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TABLE 1. Percentage of BrdU positive S phase Cos-1 epithelial cells following 674 
transfection with wild type and mutant HPV1 E4 expression plasmidsa 
 676 
 
 678 
 
 680 
 
 682 
 
 684 
 
 
a
Data taken from four independent experiments and results are shown as the means 686 
± standard deviations. 
HPV1 E4 % of BrdU-positive S 
phase cells 
E4-17K 
E4-16K 
E4-17/16K 
E4-17K"2-5/16K 
E4-17K"10-14/16K 
E4-17K"21-24/16K 
E4-17K"24-27/16K 
E4-17K"27-30/16K 
E4-17K"32-33/16K 
E4-17K"44-48/16K 
E4-17K"49-53/16K 
E4-17K"57-60/16K 
E4-17K"110-115/16K 
E4-17K"61-125/16K 
pcDNA 
15.2 ± 1.8 
14.4 ± 1.5 
7.9   ± 0.3 
9.0   ± 1.5 
8.1   ± 1.7 
8.8   ± 1.7 
6.0   ± 1.8 
9.7   ± 1.5 
8.8   ± 1.6 
16.2 ± 1.6 
7.6   ± 0.9 
6.3   ± 1.1 
8.2   ± 0.6 
10.0 ± 1.2 
16.6 ± 2.1 
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